These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 3075164)

  • 1. Male contraception: current status and future prospects.
    Wu FC
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):443-65. PubMed ID: 3075164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of pharmaceutical compounds on male fertility.
    Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I
    Andrologia; 1976; 8(3):203-35. PubMed ID: 793446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF; Rollet J
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Male contraception in 1987].
    Silvestre L; Varin C; Bouchard P
    Rev Prat; 1987 Sep; 37(38):2302-11. PubMed ID: 3310192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target sites for suppressing fertility in the male.
    Prasad MR; Rajalakshmi M
    Adv Sex Horm Res; 1976; 2():263-87. PubMed ID: 797248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible physiological bases for contraceptive techniques in the male.
    Setchell BP
    Hum Reprod; 1994 Jun; 9(6):1081-7. PubMed ID: 7962380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Looking for the "male pill".
    Herndon N
    Netw Res Triangle Park N C; 1992 Aug; 13(1):20-3. PubMed ID: 12317724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in the control of testicular function.
    Swerdloff RS; Wang C; Bhasin S
    Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Male fertility regulation: the challenges for the year 2000.
    Waites GM
    Br Med Bull; 1993 Jan; 49(1):210-21. PubMed ID: 8324610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Male contraception: hormonal, mechanical and other.
    Comhaire FH
    Hum Reprod; 1994 Apr; 9(4):586-90. PubMed ID: 8046007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of male-fertility-regulating agents.
    Ray S; Verma P; Kumar A
    Med Res Rev; 1991 Sep; 11(5):437-72. PubMed ID: 1943328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.